Long-Term Debt - Narrative (Detail)					1 Months Ended	3 Months Ended
	May 06, 2021 d	May 01, 2019 USD ($)	Feb. 25, 2019 USD ($)	Apr. 23, 2018 $ / shares	Apr. 30, 2018 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Apr. 18, 2018 USD ($) $ / shares
Debt Instrument [Line Items]
Direct and incremental third-party expenses accounted for as debt issuance costs						$ 0	$ 397,000
Paid-in-kind interest						1,521,000	335,000
4.75% Convertible Senior Subordinated Notes due 2024
Debt Instrument [Line Items]
Term loan funded at execution						$ 165,000,000		$ 165,000,000
Debt Instrument, Frequency of Periodic Payment (in years)						five
Amortization expense on debt issuance costs						$ 700,000
Coupon interest expense						1,100,000	1,100,000
Debt instrument conversion (in USD per share) | $ / shares				$ 15.90
Debt instrument conversion premium (in percent)				20.00%
Closing price of the common stock (in USD per share) | $ / shares									$ 13.25
Percentage of common stock price	130.00%
Debt instrument, convertible, threshold trading days | d	20
Debt instrument, convertible, threshold consecutive trading days | d	30
Percentage of debt instrument redemption price	100.00%
Debt instrument, debt default, minimum percentage of aggregate principal amount due				25.00%
Costs incurred on issuance of debt					$ 6,000,000	$ 2,312,000		2,572,000
Net proceeds from issuance of long-term convertible debt					$ 159,000,000
Loan interest rate						5.47%
Debt instrument initial conversion rate				0.063
4.75% Convertible Senior Subordinated Notes due 2024 | J. Wood Capital Advisors LLC
Debt Instrument [Line Items]
Principal amount outstanding									$ 5,000,000
Purchase Agreement | 4.75% Convertible Senior Subordinated Notes due 2024
Debt Instrument [Line Items]
Principal amount outstanding									$ 135,000,000
Debt instrument, interest rate				4.75%					4.75%
Additional principal amount outstanding									$ 25,000,000
R-Bridge Loan Agreement
Debt Instrument [Line Items]
Line of credit facility, borrowing capacity						$ 60,000,000
Percentage of Initial sale on NUZYRA						2.50%
Maximum percentage of net sales adjust under certain circumstances						5.00%
Sales annual cap						$ 10,000,000
Sales annual cap adjust under certain circumstances						$ 12,000,000
Interest rate of annual rate						7.00%
Annual interest rate on event of default						10.00%
Accrued interest up to excess of principal payment						$ 15,000,000
Collection amount in excess of annual cap shared between parties						15,000,000
Excess of initial collection amount shared between parties						15,000,000
Loan capped amount						114,000,000
Event of default occurred amount						0
Net proceeds						58,300,000
Term loan funded at execution						60,000,000
Lender fees accounted for as debt discount						1,100,000
Direct and incremental third-party expenses accounted for as debt issuance costs						600,000
Costs incurred on issuance of debt						1,385,000		1,443,000
Interest expense						2,000,000	2,000,000
Paid-in-kind interest						300,000	200,000
Royalty Backed Loan Agreement
Debt Instrument [Line Items]
Costs incurred on issuance of debt						1,629,000		$ 1,673,000
Paid-in-kind interest						500,000
Royalty Backed Loan Agreement | Healthcare Royalty Partners III, L.P
Debt Instrument [Line Items]
Line of credit facility, borrowing capacity			$ 32,500,000
Interest rate of annual rate			12.00%
Interest expense						$ 1,000,000	$ 1,000,000
Proceeds from lines of credit		$ 27,800,000
Line of credit net of lender discount		500,000
Line of credit lender expenses		200,000
Line of credit deposits into interest reserve account		4,000,000
Repayment of other lender fees		$ 1,200,000
Line of credit facility, fee (in percent)			1.50%
Royalty Backed Loan Agreement | Healthcare Royalty Partners III, L.P | Maximum
Debt Instrument [Line Items]
Line of credit facility, periodic payment			$ 300,000